ContraFect Prices $10 Million Public Offering of Common Stock

Pharmaceutical Investing

ContraFect (NASDAQ:CFRX) has announced the pricing of its underwritten public offering of five million shares of its common stock at a public offering of US$2 per share. As quoted in the press release: All shares in the offering are to be sold by ContraFect. The gross proceeds from the offering will be $10 million, before …

ContraFect (NASDAQ:CFRX) has announced the pricing of its underwritten public offering of five million shares of its common stock at a public offering of US$2 per share.

As quoted in the press release:

All shares in the offering are to be sold by ContraFect. The gross proceeds from the offering will be $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect. In addition, ContraFect has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about July 31, 2018, subject to customary closing conditions.

Click here to read the full press release.

contrafect nasdaq:cfrx public offering Pharmaceutical Investing